vs
BRINKER INTERNATIONAL, INC（EAT）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
BRINKER INTERNATIONAL, INC的季度营收约是Revvity的1.9倍（$1.5B vs $772.1M），Revvity净利率更高（12.7% vs 8.7%，领先4.0%），Revvity同比增速更快（5.9% vs 3.2%），过去两年BRINKER INTERNATIONAL, INC的营收复合增速更高（10.3% vs 9.0%）
Brinker International, Inc.是美国跨国餐饮企业，成立于1975年，总部位于得克萨斯州达拉斯，旗下拥有Chili's和Maggiano's Little Italy两大知名连锁餐饮品牌，目前在全球持有、运营或特许经营的上述品牌门店总计达1672家。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
EAT vs RVTY — 直观对比
营收规模更大
EAT
是对方的1.9倍
$772.1M
营收增速更快
RVTY
高出2.7%
3.2%
净利率更高
RVTY
高出4.0%
8.7%
两年增速更快
EAT
近两年复合增速
9.0%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.5B | $772.1M |
| 净利润 | $127.9M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 11.3% | 14.5% |
| 净利率 | 8.7% | 12.7% |
| 营收同比 | 3.2% | 5.9% |
| 净利润同比 | — | 3.9% |
| 每股收益（稀释后） | $2.87 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EATRVTY
| Q1 26 | $1.5B | — | ||
| Q4 25 | $1.5B | $772.1M | ||
| Q3 25 | $1.3B | $698.9M | ||
| Q2 25 | $1.5B | $720.3M | ||
| Q1 25 | $1.4B | $664.8M | ||
| Q4 24 | $1.4B | $729.4M | ||
| Q3 24 | $1.1B | $684.0M | ||
| Q2 24 | $1.2B | $691.7M |
净利润EATRVTY
| Q1 26 | $127.9M | — | ||
| Q4 25 | $128.5M | $98.4M | ||
| Q3 25 | $99.5M | $46.7M | ||
| Q2 25 | $107.0M | $53.9M | ||
| Q1 25 | $119.1M | $42.2M | ||
| Q4 24 | $118.5M | $94.6M | ||
| Q3 24 | $38.5M | $94.4M | ||
| Q2 24 | $57.3M | $55.4M |
毛利率EATRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% |
营业利润率EATRVTY
| Q1 26 | 11.3% | — | ||
| Q4 25 | 11.6% | 14.5% | ||
| Q3 25 | 8.7% | 11.7% | ||
| Q2 25 | 9.8% | 12.6% | ||
| Q1 25 | 11.0% | 10.9% | ||
| Q4 24 | 11.5% | 16.3% | ||
| Q3 24 | 5.0% | 14.3% | ||
| Q2 24 | 6.1% | 12.4% |
净利率EATRVTY
| Q1 26 | 8.7% | — | ||
| Q4 25 | 8.8% | 12.7% | ||
| Q3 25 | 7.4% | 6.7% | ||
| Q2 25 | 7.3% | 7.5% | ||
| Q1 25 | 8.4% | 6.4% | ||
| Q4 24 | 8.7% | 13.0% | ||
| Q3 24 | 3.4% | 13.8% | ||
| Q2 24 | 4.7% | 8.0% |
每股收益（稀释后）EATRVTY
| Q1 26 | $2.87 | — | ||
| Q4 25 | $2.86 | $0.86 | ||
| Q3 25 | $2.17 | $0.40 | ||
| Q2 25 | $2.31 | $0.46 | ||
| Q1 25 | $2.56 | $0.35 | ||
| Q4 24 | $2.61 | $0.77 | ||
| Q3 24 | $0.84 | $0.77 | ||
| Q2 24 | $1.22 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | $424.4M | — |
| 股东权益账面价值 | $406.0M | $7.3B |
| 总资产 | $2.8B | $12.2B |
| 负债/权益比越低杠杆越低 | 1.05× | — |
8季度趋势，按日历期对齐
现金及短期投资EATRVTY
| Q1 26 | — | — | ||
| Q4 25 | $15.0M | $919.9M | ||
| Q3 25 | $33.6M | $931.4M | ||
| Q2 25 | $18.9M | $991.8M | ||
| Q1 25 | $17.5M | $1.1B | ||
| Q4 24 | $14.8M | $1.2B | ||
| Q3 24 | $16.2M | $1.2B | ||
| Q2 24 | $64.6M | $2.0B |
总债务EATRVTY
| Q1 26 | $424.4M | — | ||
| Q4 25 | $451.3M | — | ||
| Q3 25 | $525.8M | — | ||
| Q2 25 | $426.0M | — | ||
| Q1 25 | $518.3M | — | ||
| Q4 24 | $652.0M | — | ||
| Q3 24 | $806.9M | — | ||
| Q2 24 | $786.3M | — |
股东权益EATRVTY
| Q1 26 | $406.0M | — | ||
| Q4 25 | $379.3M | $7.3B | ||
| Q3 25 | $343.9M | $7.4B | ||
| Q2 25 | $370.9M | $7.6B | ||
| Q1 25 | $259.0M | $7.6B | ||
| Q4 24 | $131.5M | $7.7B | ||
| Q3 24 | $12.7M | $7.9B | ||
| Q2 24 | $39.4M | $7.9B |
总资产EATRVTY
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.7B | $12.2B | ||
| Q3 25 | $2.7B | $12.1B | ||
| Q2 25 | $2.7B | $12.4B | ||
| Q1 25 | $2.6B | $12.4B | ||
| Q4 24 | $2.6B | $12.4B | ||
| Q3 24 | $2.5B | $12.8B | ||
| Q2 24 | $2.6B | $13.4B |
负债/权益比EATRVTY
| Q1 26 | 1.05× | — | ||
| Q4 25 | 1.19× | — | ||
| Q3 25 | 1.53× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 2.00× | — | ||
| Q4 24 | 4.96× | — | ||
| Q3 24 | 63.54× | — | ||
| Q2 24 | 19.96× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $571.8M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | 4.47× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流EATRVTY
| Q1 26 | $571.8M | — | ||
| Q4 25 | $218.9M | $182.0M | ||
| Q3 25 | $120.8M | $138.5M | ||
| Q2 25 | $186.0M | $134.3M | ||
| Q1 25 | $212.0M | $128.2M | ||
| Q4 24 | $218.2M | $174.2M | ||
| Q3 24 | $62.8M | $147.9M | ||
| Q2 24 | $141.5M | $158.6M |
自由现金流EATRVTY
| Q1 26 | — | — | ||
| Q4 25 | $155.2M | $161.8M | ||
| Q3 25 | $62.2M | $120.0M | ||
| Q2 25 | $106.1M | $115.5M | ||
| Q1 25 | $132.4M | $112.2M | ||
| Q4 24 | $168.9M | $149.8M | ||
| Q3 24 | $6.3M | $125.6M | ||
| Q2 24 | $83.5M | $136.6M |
自由现金流率EATRVTY
| Q1 26 | — | — | ||
| Q4 25 | 10.7% | 21.0% | ||
| Q3 25 | 4.6% | 17.2% | ||
| Q2 25 | 7.3% | 16.0% | ||
| Q1 25 | 9.3% | 16.9% | ||
| Q4 24 | 12.4% | 20.5% | ||
| Q3 24 | 0.6% | 18.4% | ||
| Q2 24 | 6.9% | 19.7% |
资本支出强度EATRVTY
| Q1 26 | — | — | ||
| Q4 25 | 4.4% | 2.6% | ||
| Q3 25 | 4.3% | 2.6% | ||
| Q2 25 | 5.5% | 2.6% | ||
| Q1 25 | 5.6% | 2.4% | ||
| Q4 24 | 3.6% | 3.4% | ||
| Q3 24 | 5.0% | 3.3% | ||
| Q2 24 | 4.8% | 3.2% |
现金转化率EATRVTY
| Q1 26 | 4.47× | — | ||
| Q4 25 | 1.70× | 1.85× | ||
| Q3 25 | 1.21× | 2.97× | ||
| Q2 25 | 1.74× | 2.49× | ||
| Q1 25 | 1.78× | 3.03× | ||
| Q4 24 | 1.84× | 1.84× | ||
| Q3 24 | 1.63× | 1.57× | ||
| Q2 24 | 2.47× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EAT
| Company sales | $1.5B | 99% |
| Franchise revenues | $14.7M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
